The China Task Force focuses on advancing pulmonary vascular disease care and research across China. The Task Force brings together clinicians, researchers, and institutions to strengthen clinical practice, education, and research, while promoting collaboration within China and internationally through PVRI.
Objectives
The Task Force aims to drive technological progress in the field of pulmonary vascular medicine across China and the broader Asia-Pacific region in the following ways:
strengthen and expand national registries and cohort studies for pulmonary embolism (PE), chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary arterial hypertension (PAH), and PH associated with chronic lung diseases
advance clinical diagnosis and treatment of pulmonary vascular diseases
support professional training and education for healthcare providers
promote translational and clinical research, including the integration of emerging technologies
foster domestic and international academic exchange through collaboration with PVRI and global partners
support the integration of artificial intelligence and innovative vascular interventional techniques into clinical practice and research.
Recent activities
In 2025 the China Task Force has:
expanded a national registry network for venous thromboembolism (VTE), PE, and CTEPH. This comprised of 153 PE centres, 123 VTE centres, 20 CTEPH centres, and 39 specialised right heart catheterisation and interventional centres — enrolling over 100,000 patients across multiple cohorts
contributed to international research collaborations, including the TEAM registry and the GoDeep study group
hosted the PVRI–China Seminar in Kunming, China. The had in-person participation from PVRI experts and over 1,000 attendees, strengthening academic exchange and laying foundations for future collaborative research.
In 2026, the Task Force aims to:
launch a Young Education Group and enhance global networking for early-career scientists within the PVRI framework
launch a dedicated webinar series on imaging/research
host the next annual PVRI China Task Force meeting
If you are interested in joining this Task Force, please get in touch.
Our Regional Task Forces don't yet have global coverage. If you're interested in starting one, please contact us.
Interested in accessing global data on PH patient experience? Almost 4,000 patients and carers across 85 countries completed Phase 1 of our PH Global Patient Survey (PHGPS). Questions across all PH groups included diagnostic tests & timelines, genetic testing, treatments, financial burdens, hospital visits, research participation, quality of life, telemedicine, patient-reported outcome measures, and self-monitoring with digital technology. The findings have the potential to improve patient care, guide future research and help us address unmet needs.
